Strengthening Medicare for Patients and Providers Act - HR 2474
Comments submitted: Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies
Comments submitted: Notice of Benefit and Payment Parameters for 2025
Medicare physician reimbursement: HR 6683 - Preserving Seniors Access to Physicians Act of 2023;
HR 6371 - Provider Reimbursement Stability Act of 2023
Medicare fee schedule: H.R.6545 - Physician Fee Schedule Update and Improvements Act
Halt the 3.4% cut to physician payments in the 2024 Medicare fee schedule
Comments submitted: CMS Comprehensive Ocular Care MVP
Comments submitted: Draft Report and Plan on Best Practices for Guidance (Docket No. FDA-2023-N-5653)
Response to House Education and Workforce RFI: Reforms to Increase Affordability and Quality in Employer-Sponsored Health Coverage
Duration: January 1, 2008
to
present
General Issues: Medicare/Medicaid , Health Issues , Medical/Disease Research/Clinical Labs , Pharmacy , Veterans , Telecommunications , Copyright/Patent/Trademark
Spending: about $10,000,046 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 22.
Original Filing: 301570595.xml
Lobbying Issues
Strengthening Medicare for Patients and Providers Act - HR 2474
Comments submitted: Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies
Comments submitted: Notice of Benefit and Payment Parameters for 2025
Medicare physician reimbursement: HR 6683 - Preserving Seniors Access to Physicians Act of 2023;
HR 6371 - Provider Reimbursement Stability Act of 2023
Medicare fee schedule: H.R.6545 - Physician Fee Schedule Update and Improvements Act
Halt the 3.4% cut to physician payments in the 2024 Medicare fee schedule
Comments submitted: CMS Comprehensive Ocular Care MVP
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Comments submitted: Draft Report and Plan on Best Practices for Guidance (Docket No. FDA-2023-N-5653)
Response to House Education and Workforce RFI: Reforms to Increase Affordability and Quality in Employer-Sponsored Health Coverage
Agencies Lobbied
U.S. House of Representatives Food & Drug Administration (FDA)
1st Quarter, 2024
AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY filed a lobbying registration on April 7 for in-house lobbying efforts, effective Jan. 15.
Original Filing: 301546970.xml
Issue(s) they said they’d lobby about: Medicare physician fee schedule
CMS Medicare coverage policy
Ambulatory surgical center payment issues
Medicare Access and Chip Reauthorization Act (MACRA)
Graduate Medical Education
FDA drug shortage issues
Medicare Advantage prior authorization policies .
1st Quarter, 2024
AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY filed a lobbying registration on Feb. 2 for in-house lobbying efforts, effective Jan. 16.
Original Filing: 301542761.xml
Issue(s) they said they’d lobby about: Medicare physician fee schedule
CMS Medicare coverage policy
Ambulatory surgical center payment issues
Medicare Access and Chip Reauthorization Act (MACRA)
Graduate Medical Education
FDA drug shortage issues
Medicare Advantage prior authorization policies .
4th Quarter, 2023
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 19.
Original Filing: 301530171.xml
Lobbying Issues
Medicare physician reimbursement: HR 6683 - Preserving Seniors Access to Physicians Act of 2023;
HR 6371 - Provider Reimbursement Stability Act of 2023
Medicare fee schedule: H.R.6545 - Physician Fee Schedule Update and Improvements Act
Halt the 3.4% cut to physician payments in the 2024 Medicare fee schedule
Opposition to the implementation of CMS add-on code G2211
CMS episode-based payment models
Misattribution of diabetes cost measure to MIPS Scores for Ophthalmologists
Oppose proposed Local Coverage Determination (LCD) on Minimally Invasive Glaucoma Surgery (MIGS)
Response to Republican House Budget Committee Health Care Task Force Request for Information on Modernizing Healthcare and Reducing Spending
Ensuring telehealth practitioners working from a home-based (or other) location do not need to report that private residence to the federal government for purposes of either enrollment or billing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
3rd Quarter, 2023
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 18, 2023.
Original Filing: 301503706.xml
Lobbying Issues
Medicare physician reimbursement; HR 2474-Strengthening Medicare for Patients and Providers Act
Opposition to the implementation of CMS add-on code G2211
CMS episode-based payment models
Cost Episode MIPS Scores for Ophthalmologists
Ambulatory surgery center (ASC) reimbursement issues
Medicare Advantage utilization management, including prior authorization and step therapy: S. 652/HR 2630-the Safe Step Act
Graduate Medical Education (GME): S 1302-Resident Physician Shortage Reduction Act of 2023
Oversight of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
compounding of bulk moxifloxacin
Agencies Lobbied
Food & Drug Administration (FDA)
Lobbying Issues
Veterans Affairs National Standards of Practice
Agencies Lobbied
Veterans Affairs - Dept of (VA)
2nd Quarter, 2023
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301486721.xml
Lobbying Issues
Medicare physician reimbursement; HR 2474-Strengthening Medicare for Patients and Providers Act
Ambulatory surgery center (ASC) reimbursement issues
Medicare Advantage utilization management, including prior authorization and step therapy: S. 652-the Safe Step Act
Pass-through payments for ophthalmic products
Scope of practice issues: H.R. 2713-Improving Care and Access to Nurses Act
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization
Graduate Medical Education (GME): S 1302-Resident Physician Shortage Reduction Act of 2023
Oversight of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
compounding of bulk moxifloxacin
Agencies Lobbied
Food & Drug Administration (FDA)
1st Quarter, 2023
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 12, 2023.
Original Filing: 301450984.xml
Lobbying Issues
Medicare physician reimbursement
Ambulatory surgery center (ASC) reimbursement issues
Medicare Advantage utilization management, including prior authorization and step therapy
Pass-through payments for ophthalmic products
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
4th Quarter, 2022
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 19, 2023.
Original Filing: 301434304.xml
Lobbying Issues
Medicare physician reimbursement issues
Merit-Based Incentive Payment System (MIPS)
Advanced Alternative Payment (APM) models
Quality Payment Program (QPP)
Misvalued global surgical codes
Ambulatory Surgical Center (ASC) reimbursement issues
Telehealth programs and reimbursement
Health Information Technology (HIT)
Medicare Advantage utilization management, including prior authorization and step therapy
Pass-Through payments for ophthalmic products
Office-based ophthalmic surgery
H.R.3173-Improving Seniors' Timely Access to Care Act of 2021
H.R.3322-Medicare Patient Empowerment Act of 2021
H.R.7995-GOLD CARD Act of 2022
H.R.8800-Supporting Medicare Providers Act of 2022
S.826-Medicare Patient Empowerment Act of 2021
S.3018-Improving Seniors' Timely Access to Care Act of 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB)
Lobbying Issues
Compounded drugs
H.R.7667-Food and Drug Amendments of 2022
S.4333-CLEAR Act
S.4348-FDASLA Act of 2022
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Telehealth programs and reimbursement
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2022
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 17, 2022.
Original Filing: 301406208.xml
Lobbying Issues
Medicare physician reimbursement issues
Merit-Based Incentive Payment System (MIPS)
Advanced Alternative Payment (APM) models
Quality Payment Program (QPP)
Misvalued global surgical codes
Ambulatory Surgical Center (ASC) reimbursement issues
Telehealth programs and reimbursement
Health Information Technology (HIT)
Medicare Advantage utilization management, including prior authorization and step therapy
Pass-Through payments for ophthalmic products
Office-based ophthalmic surgery
H.R.3173-Improving Seniors' Timely Access to Care Act of 2021
H.R.3322-Medicare Patient Empowerment Act of 2021
H.R.7995-GOLD CARD Act of 2022
H.R.8800-Supporting Medicare Providers Act of 2022
S.826-Medicare Patient Empowerment Act of 2021
S.3018-Improving Seniors' Timely Access to Care Act of 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB)
Lobbying Issues
Compounded drugs
H.R.7667-Food and Drug Amendments of 2022
S.4333-CLEAR Act
S.4348-FDASLA Act of 2022
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Telehealth programs and reimbursement
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2022
AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY amended a lobbying report for in-house lobbying in Q22022 on Aug. 25, 2022
Original Filing: 301399416.xml
Lobbying Issues
Medicare physician reimbursement issues
Merit-Based Incentive Payment System (MIPS)
Advanced Alternative Payment (APM) models
Quality Payment Program (QPP)
Misvalued global surgical codes
Ambulatory Surgical Center (ASC) reimbursement issues
Telehealth programs and reimbursement
Health Information Technology (HIT)
Medicare Advantage utilization management, including prior authorization and step therapy
Pass-Through payments for ophthalmic products
H.R.3173-Improving Seniors' Timely Access to Care Act of 2021
H.R.3322-Medicare Patient Empowerment Act of 2021
H.R.7995-GOLD CARD Act of 2022
S.826-Medicare Patient Empowerment Act of 2021
S.3018-Improving Seniors' Timely Access to Care Act of 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB)
Lobbying Issues
H.R.7667-Food and Drug Amendments of 2022
S.4333-CLEAR Act
S.4348-FDASLA Act of 2022
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Telehealth programs and reimbursement
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2022
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301390374.xml
Lobbying Issues
H.R. 7667-Food and Drug Amendments of 2022
S.4333-CLEAR Act
S.4348-FDASLA Act of 2022
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare physician reimbursement issues
Merit-Based Incentive Payment System (MIPS)
Advanced Alternative Payment (APM) models
Quality Payment Program (QPP)
Misvalued global surgical codes
Ambulatory Surgical Center (ASC) reimbursement issues
Telehealth programs and reimbursement
Health Information Technology (HIT)
Medicare Advantage utilization management, including prior authorization and step therapy
Pass-Through payments for ophthalmic products
H.R.3173-Improving Seniors' Timely Access to Care Act of 2021
H.R.3322-Medicare Patient Empowerment Act of 2021
H.R.7995-GOLD CARD Act of 2022
S.826-Medicare Patient Empowerment Act of 2021
S.3018-Improving Seniors' Timely Access to Care Act of 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS) Office of Management & Budget (OMB)
Lobbying Issues
Telehealth programs and reimbursement
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2022
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 7, 2022.
Original Filing: 301344049.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payments models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2022
AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY filed a lobbying registration on April 4, 2022 for in-house lobbying efforts, effective Jan. 5, 2022.
Original Filing: 301343597.xml
Issue(s) they said they’d lobby about: Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payments models (APMs), Quality Payment program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes. .
4th Quarter, 2021
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 14, 2022.
Original Filing: 301322402.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payments models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
3rd Quarter, 2021
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 19, 2021.
Original Filing: 301305670.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payments models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2021
AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY amended a lobbying report for in-house lobbying in Q22021 on July 19, 2021
Original Filing: 301281577.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payments models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2021
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 19, 2021.
Original Filing: 301281385.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payments models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2021
AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY amended a lobbying report for in-house lobbying in Q22021 on July 19, 2021
Original Filing: 301281741.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payments models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2021
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 19, 2021.
Original Filing: 301259167.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payments models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2020
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 13, 2021.
Original Filing: 301230801.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payment models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
3rd Quarter, 2020
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 13, 2020.
Original Filing: 301208962.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payment models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2020
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 17, 2020.
Original Filing: 301192078.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payment models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2020
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 17, 2020.
Original Filing: 301169398.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payment models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2019
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 17, 2020.
Original Filing: 301108630.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payment models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy, evaluation & management codes, add-on codes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
3rd Quarter, 2019
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 21, 2019.
Original Filing: 301076163.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payment models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2019
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 12, 2019.
Original Filing: 301044866.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payment models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2019
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 15, 2019.
Original Filing: 301025217.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), advanced alternative payment models (APMs), Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2018
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 18, 2019.
Original Filing: 301008903.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS) and Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
3rd Quarter, 2018
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 16, 2018.
Original Filing: 300985802.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS) and Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues, prior authorization and step therapy
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2018
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 24, 2018.
Original Filing: 300979242.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS) and Quality Payment Program (QPP), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2018
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 6, 2018.
Original Filing: 300942735.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS) and Quality Payment Program (QPP), misvalued codes, repeal of Independent Payment Advisory Board (IPAB), ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2017
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 16, 2018.
Original Filing: 300923982.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS) and Quality Payment Program (QPP), misvalued codes, repeal of Independent Payment Advisory Board (IPAB), ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
3rd Quarter, 2017
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 13, 2017.
Original Filing: 300903853.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS) and Quality Payment Program (QPP), misvalued codes, repeal of Independent Payment Advisory Board (IPAB), ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2017
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 10, 2017.
Original Filing: 300882908.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS) and Quality Payment Program (QPP), misvalued codes, repeal of Independent Payment Advisory Board (IPAB), ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2017
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 11, 2017.
Original Filing: 300863957.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS) and Quality Payment Program (QPP), misvalued codes, repeal of Independent Payment Advisory Board (IPAB), ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, off-label communication, health information technology, healthcare reform, health insurer anti-trust issues
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2016
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 27, 2017.
Original Filing: 300859301.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), misvalued codes, restoring cuts to glaucoma and retina codes in Medicare Physician Fee Schedule, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, health information technology, healthcare reform, health insurer anti-trust issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
3rd Quarter, 2016
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 17, 2016.
Original Filing: 300828425.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), misvalued codes, restoring cuts to glaucoma and retina codes in Medicare Physician Fee Schedule, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, health information technology, healthcare reform, meaningful use stage 3 and modifications, office-based surgical suite cataract surgery, health insurer anti-trust issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2016
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 18, 2016.
Original Filing: 300812159.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), misvalued codes, restoring cuts to glaucoma and retina codes in Medicare Physician Fee Schedule, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, health information technology, healthcare reform, meaningful use stage 3 and modifications, office-based surgical suite cataract surgery, health insurer anti-trust issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2016
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 14, 2016.
Original Filing: 300791127.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), misvalued codes, ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, health information technology, healthcare reform, meaningful use stage 3 and modifications, ICD-10 implementation, office-based surgical suite cataract surgery, health insurer anti-trust issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2015
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 15, 2016.
Original Filing: 300772478.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, health information technology, healthcare reform, meaningful use stage 3 and modifications, ICD-10 implementation, office-based surgical suite cataract surgery, health insurer anti-trust issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
3rd Quarter, 2015
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 14, 2015.
Original Filing: 300752811.xml
Lobbying Issues
Medicare reimbursement issues, Merit-Based Incentive Payment System (MIPS), ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, health information technology, healthcare reform, meaningful use stage 3 and modifications, ICD-10 implementation, office-based surgical suite cataract surgery, health insurer anti-trust issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2015
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 17, 2015.
Original Filing: 300738838.xml
Lobbying Issues
Medicare reimbursement issues, Sustainable Growth Rate formula (H.R. 2), ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, health information technology, healthcare reform, preventing the elimination of the CMS policy to transition 10- and 90-day global codes to 0-day, meaningful use stage 3 and flexibility, ICD-10 implementation
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2015
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 10, 2015.
Original Filing: 300713945.xml
Lobbying Issues
Medicare reimbursement issues, Sustainable Growth Rate formula (H.R. 2), ambulatory surgery centers, ophthalmic legislation, FDA-related issues, compounded drug issues, quality issues, health information technology, healthcare reform, preventing the elimination of the CMS policy to transition 10- and 90-day global codes to 0-day
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2014
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 20, 2015.
Original Filing: 300702310.xml
Lobbying Issues
Medicare reimbursement issues; Sustainable Growth Rate formula; ambulatory surgery centers; ophthlalmic legislation; FDA-related issues; compounded drugs issues; quality issues; health information technology; healthcare reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2014
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 16, 2014.
Original Filing: 300678156.xml
Lobbying Issues
Medicare reimbursement issues; Sustainable Growth Rate formula; ambulatory surgery centers; ophthlalmic legislation; FDA-related issues; compounded drugs issues; quality issues; health information technology; healthcare reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2014
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 14, 2014.
Original Filing: 300656254.xml
Lobbying Issues
Medicare reimbursement issues; Sustainable Growth Rate formula; ambulatory surgery centers, ophthalmic legislation; FDA-related issues; compounded drugs issues; health information technology; healthcare reform.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Food & Drug Administration (FDA) Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
1st Quarter, 2014
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 14, 2014.
Original Filing: 300634863.xml
Lobbying Issues
Medicare reimbursement issues; Sustainable Growth Rate formula; ambulatory surgery centers; ophthlalmic legislation; FDA-related issues; compounded drugs issues; quality issues; health information technology; healthcare reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2013
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 17, 2014.
Original Filing: 300617627.xml
Lobbying Issues
Medicare reimbursement issues; Sustainable Growth Rate formula; ambulatory surgery centers; ophthlalmic legislation; FDA-related issues; compounded drugs issues; quality issues; health information technology; healthcare reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2013
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 15, 2013.
Original Filing: 300593882.xml
Lobbying Issues
medicare reimbursement issues; Sustainable Growth Rate formula; ambulatory surgery center; ophthlalmic legislation; FDA-related issues; compounded drugs issues; quality issues; health information technology; healthcare reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2013
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 16, 2013.
Original Filing: 300572627.xml
Lobbying Issues
medicare reimbursement issues; practice expense; ambulatory surgery center; opthlalmic legislation; FDA-related issues; compounded drugs issues; quality issues; health information technology; healthcare reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2013
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 16, 2013.
Original Filing: 300550526.xml
Lobbying Issues
medicare reimbursement issues; practice expense; ambulatory surgery center; opthlalmic legislation; FDA-related issues; quality issues; health information technology; healthcare reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2012
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 11, 2013.
Original Filing: 300527435.xml
Lobbying Issues
medicare reimbursement issues; practice expense; ambulatory surgery center; opthlalmic legislation; FDA-related issues; quality issues; health information technology; healthcare reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
3rd Quarter, 2012
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 24, 2012.
Original Filing: 300522737.xml
Lobbying Issues
medicare reimbursement issues; practice expense; ambulatory surgery center; opthlalmic legislation; FDA-related issues; quality issues; health information technology; healthcare reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2012
AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY amended a lobbying report for in-house lobbying in Q22012 on Sept. 28, 2012
Original Filing: 300503318.xml
Lobbying Issues
medicare reimbursement issues; practice expense; ambulatory surgery center payments; optometric legislation; FDA related issues; quality issues; health information technology; healthcare reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2012
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 17, 2012.
Original Filing: 300462786.xml
Lobbying Issues
medicare reimbursement issues; practice expense; ambulatory surgery center payments; optometric legislation; FDA related issues; quality issues; health information technology; health care reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2011
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 20, 2012.
Original Filing: 300451110.xml
Lobbying Issues
medicare reimbursement issues; practice expense; ambulatory surgery center payments; optometric legislation; FDA related issues; qulilty issues; health information technology; health care reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
3rd Quarter, 2011
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 20, 2011.
Original Filing: 300423582.xml
Lobbying Issues
medicare reimbursement issues; practice expense; ambulatory surgery center payments; optometric legistlation; FDA relate issues; quality issues; health information technolgy; health care reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2011
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 21, 2011.
Original Filing: 300406251.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; ambulatory surgery center payments; optometric legislation; FDA related issues; quality issues; health information technology; health care reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2011
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 20, 2011.
Original Filing: 300375960.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; ambulatory surgical center payments; optometric legislation; FDA related issues; quality issues; health information technology; health care reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2010
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 20, 2011.
Original Filing: 300350755.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; ambulatory surgery center payments; optometric legislation; FDA related issues; quality issues; health information technology; health care reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
3rd Quarter, 2010
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 20, 2010.
Original Filing: 300322310.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; ambulatory surgical center payments; optometric legislation; FDA related issues; quality issues; health information technology; health care reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2010
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 20, 2010.
Original Filing: 300295793.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; ambulatory surgical center payments; optometric legislation; FDA related issues; quality issues; health information technology; health care reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2010
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 20, 2010.
Original Filing: 300269254.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; ambulatory surgical center payments; optometric legistlation; FDA related issues; quality issues; health information technology; health care reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2009
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 19, 2010.
Original Filing: 300237222.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; ambulatory surgical center payments; optometric legislation; FDA related issues; qaulity issue; health information technology; health care reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
3rd Quarter, 2009
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 19, 2009.
Original Filing: 300214552.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; ambulatory surgical center payments; optometric legislation; FDA related issues: quality issue: health information technology; health care reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2009
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 20, 2009.
Original Filing: 300191703.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; abmulatory surgical center payments; optometric legislation; FDA-related issues;quality issues
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) U.S. House of Representatives U.S. Senate
1st Quarter, 2009
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 27, 2009.
Original Filing: 300167258.xml
Lobbying Issues
Medicare Reimbursement issues; practice expense; ambulatory surgical center payments; optometric legislation; FDA related issues; quality issues; health information technology
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
4th Quarter, 2008
In Q4, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Jan. 21, 2009.
Original Filing: 300131770.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; ambulatory surgical center payments, optometric legislation; FDA-related issues, quality issues
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS) U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
In Q3, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on Oct. 17, 2008.
Original Filing: 300099263.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; ambulatory surgical center payments; optometric legislation; FDA-related issues; quality initiatives
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
2nd Quarter, 2008
In Q2, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on July 17, 2008.
Original Filing: 300069454.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; ambulatory surgical center payments; optometric legislation; FDA-related issues
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2008
In Q1, AMERICAN SOCIETY OF CATARACT & REFRACTIVE SURGERY had in-house lobbyists. The report was filed on April 18, 2008.
Original Filing: 300045430.xml
Lobbying Issues
Medicare reimbursement issues; practice expense; ambulatory surgical center payments; optometric legislation; FDA-related issues
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate